Mechanisms, when to use each class, and the exceptions Step 2 CK and the NBME shelf love to test.
1. Medication Classes Overview
| Class | Primary action | Example drugs |
|---|---|---|
| Anticoagulants | Inhibit coagulation factors (clotting cascade) | Heparin, warfarin, DOACs (e.g., apixaban) |
| Antiplatelets | Inhibit platelet aggregation | Aspirin, clopidogrel, ticagrelor |
| Thrombolytics | Break down existing clots (fibrinolysis) | Alteplase, tenecteplase |
| Antithrombotics | Umbrella term for anticoagulants and antiplatelets | Not a separate drug class |
2. Mechanism of Action Comparison
| Drug class | Target | Mechanism |
|---|---|---|
| Anticoagulants | Clotting factors (e.g., Xa, IIa) | Block thrombin generation; prevent fibrin clot formation |
| Antiplatelets | Platelet receptors and enzymes (e.g., P2Y12, COX-1) | Prevent platelet plug formation |
| Thrombolytics | Plasminogen → plasmin activation | Lyse existing fibrin clots |
3. Clinical Use Cases
| Scenario | Drug class of choice | Examples |
|---|---|---|
| Atrial fibrillation (stroke prevention) | Anticoagulant | Apixaban, rivaroxaban, dabigatran, warfarin |
| DVT/PE (treatment and prevention) | Anticoagulant | Heparin → warfarin, or a DOAC |
| Acute MI | Antiplatelet plus anticoagulant | Aspirin + P2Y12 inhibitor + heparin |
| Ischemic stroke within 4.5 hours of onset | Thrombolytic, if no contraindication | Alteplase or tenecteplase |
| Mechanical heart valve | Anticoagulant (warfarin only) | Warfarin; INR goal depends on valve position and risk (e.g., 2.5–3.5 for a mechanical mitral valve) |
| PAD, stable CAD, TIA prevention | Antiplatelet | Aspirin or clopidogrel |
| STEMI when timely PCI isn't available | Thrombolytic + antiplatelet + anticoagulant | Fibrinolytic + aspirin + clopidogrel + heparin |
| After PCI with a stent | Dual antiplatelet therapy (DAPT) | Aspirin + clopidogrel or ticagrelor (typically 6 months for stable CAD, 12 months after ACS) |
4. Key Step 2/CK + NBME Tips
Anticoagulants = prevent new clots (do not break existing ones).
Thrombolytics = used acutely to dissolve thrombi (e.g., ischemic stroke, STEMI without PCI).
Antiplatelets = arterial clots (e.g., coronary, cerebral) — platelets matter more in high-flow systems.
Anticoagulants = venous clots (DVT/PE) — coagulation cascade driven.
Never combine anticoagulants + antiplatelets long term unless absolutely indicated (↑↑ bleeding risk).
Thrombolytics are contraindicated in most cases of recent surgery, active bleeding, or hemorrhagic stroke history.
Mnemonic: "PAT-A"
| Letter | Stands for | Clot type | Memory clue |
|---|---|---|---|
| P | Platelet inhibitors | Arterial clots | Think plaque and platelets |
| A | Anticoagulants | Venous clots | Think AFib and DVT |
| T | Thrombolytics | Clot busting now | Time-sensitive tPA |
| A | Antithrombotics | Umbrella term | “A” for all-encompassing |
Drug Quick Sheet
| Drug | Class | Main uses | Reversal |
|---|---|---|---|
| Heparin | Anticoagulant | DVT, PE, ACS | Protamine sulfate |
| Warfarin | Anticoagulant | AFib, mechanical valves | Vitamin K plus 4-factor PCC (FFP if PCC unavailable) |
| Apixaban, rivaroxaban | DOAC (factor Xa inhibitor) | AFib, DVT/PE | Andexanet alfa or 4-factor PCC |
| Dabigatran | DOAC (direct thrombin inhibitor) | AFib, DVT/PE | Idarucizumab |
| Aspirin | Antiplatelet | ACS, stroke prevention | No specific antidote (platelet transfusion in selected bleeding) |
| Clopidogrel | Antiplatelet | After PCI, stroke prevention | No specific antidote |
| Alteplase (tPA) | Thrombolytic | Ischemic stroke, STEMI, massive PE | Cryoprecipitate; tranexamic acid or aminocaproic acid |
Master table: exceptions and nuance
| Class | Main mechanism | Primary use | When to use | Avoid or use caution |
|---|---|---|---|---|
| Anticoagulants | Inhibit the coagulation cascade (Xa, IIa) | VTE, AFib, mechanical valves | VTE treatment; AFib stroke prevention; mechanical valves (warfarin) | Active bleeding, hemorrhagic stroke, recent major surgery or trauma. In end-stage kidney disease most DOACs are avoided; warfarin or apixaban is used |
| Antiplatelets | Inhibit platelet aggregation (COX-1, P2Y12) | Arterial disease (ACS, stroke, PAD) | MI and stroke prevention; DAPT after a stent | GI bleeding history (relative), aspirin hypersensitivity; not effective for DVT/PE |
| Thrombolytics | Activate plasmin to lyse clots | Ischemic stroke, STEMI, massive PE | Stroke within 4.5 hours; STEMI without timely PCI; PE with hypotension | BP above 185/110 that can't be lowered, prior hemorrhagic stroke, recent major surgery, active internal bleeding |
| Antithrombotics | Umbrella term | Platelets plus coagulation | Any setting that needs clot prevention | Not a specific drug class |
NBME/Step-Style Exceptions
1. Atrial Fibrillation
Use anticoagulants to prevent embolic stroke.
Don’t use aspirin alone unless patient is at low CHA₂DS₂-VASc score (e.g., score = 0).
Mechanical heart valve → must use warfarin (NOT DOACs like apixaban).
2. Post-MI
Dual antiplatelet therapy (DAPT) (aspirin + clopidogrel/ticagrelor) after PCI.
Avoid triple therapy (anticoagulant + 2 antiplatelets) unless compelling indication — increased bleeding risk.
If patient is on warfarin for Afib + just got a stent, limit DAPT duration and monitor closely.
3. Ischemic Stroke
Thrombolytics (alteplase or tenecteplase) within 4.5 hours of onset if the patient meets criteria.
Do NOT give tPA if:
BP >185/110
INR >1.7
Platelets <100k
Glucose under 50 mg/dL (correct it, then reassess)
Stroke >1/3 of MCA territory on CT
4. DVT/PE
Start with heparin, then bridge to warfarin or start DOAC directly.
Use caution with DOACs when CrCl is under 30 mL/min: most are avoided in end-stage kidney disease, where warfarin or apixaban is used.
5. Pregnancy
Use LMWH (enoxaparin) or UFH (doesn’t cross placenta).
Avoid warfarin → teratogenic, esp. in 1st trimester.
Avoid DOACs → insufficient safety data in pregnancy.
6. Massive PE with Hypotension
Use thrombolytics (alteplase) if:
Patient is unstable (shock, hypotension)
Do not delay lytics for CT angiogram if clinical signs of massive PE and patient crashing.
Summary: first-line choices and what to avoid
| Clinical scenario | First-line | Avoid |
|---|---|---|
| Nonvalvular AFib (CHA2DS2-VASc 2 or more in men, 3 or more in women) | DOAC (e.g., apixaban) | Aspirin alone |
| Mechanical heart valve | Warfarin (INR goal set by valve type and position) | DOACs |
| Ischemic stroke within 4.5 hours | Alteplase or tenecteplase | Anticoagulants in the first 24 hours after lysis |
| DVT/PE (not pregnant) | DOAC, or heparin → warfarin | Antiplatelets alone (they don't treat venous clots) |
| STEMI without timely PCI | Fibrinolytic + antiplatelet + anticoagulant | Lytics with recent major surgery or active bleeding |
| After PCI | DAPT (aspirin + clopidogrel) | Long-term triple therapy with warfarin unless clearly needed |
| DVT in pregnancy | LMWH (enoxaparin) | Warfarin, DOACs |
Reversal agents
| Drug | Reversal agent |
|---|---|
| Heparin | Protamine sulfate |
| Warfarin | Vitamin K plus 4-factor PCC (FFP if PCC unavailable) |
| Apixaban, rivaroxaban | Andexanet alfa or 4-factor PCC |
| Dabigatran | Idarucizumab |
| Alteplase (tPA) | Cryoprecipitate; tranexamic acid or aminocaproic acid |


